GO:1990269 RNA polymerase II C-terminal domain phosphoserine binding: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:1990269 describes the molecular function of binding to phosphorylated serine residues in the C-terminal domain (CTD) of RNA polymerase II.
• This binding event is mediated by specialized phosphoserine-binding modules such as the SPOC domain, tandem SH2 domains, and WW domains [1, 2, 6].
• It is essential for coupling transcription with RNA processing, termination, and post-transcriptional regulation [1, 4].
• Key proteins include Spt6, Rtr1, Scp1, Fcp1, Ess1, and the influenza polymerase subunit PA [2, 3, 5, 6, 7].
• Dysregulation of CTD phosphoserine binding is implicated in cancer, neurodegeneration, and viral pathogenesis [1, 3, 7].
• CRISPR knockout, point mutation, and knock-in models enable precise functional dissection of these interactions [1, 2].
Description
The C-terminal domain (CTD) of RNA polymerase II (Pol II) is a repetitive sequence that undergoes dynamic phosphorylation during the transcription cycle. Phosphorylation of serine residues within the CTD creates docking sites for a variety of nuclear factors that regulate transcription elongation, RNA processing, and termination. The Gene Ontology term GO:1990269, RNA polymerase II C-terminal domain phosphoserine binding, captures the molecular function of proteins that specifically recognize these phosphorylated serine marks. This function is critical for the precise coordination of gene expression and has been linked to numerous human diseases, including cancer and viral infections [1, 7]. Researchers studying transcription, RNA processing, and disease mechanisms require a clear understanding of this binding activity and the tools to investigate it.
RNA polymerase II C-terminal domain phosphoserine binding At A Glance
| GO ID | GO:1990269 |
|---|---|
| GO term | RNA polymerase II C-terminal domain phosphoserine binding |
| Ontology | molecular_function |
| Synonym | RNAP II C-terminal domain phosphoserine binding; RNA Pol II C-terminal domain phosphoserine binding |
| Major function | Binding to phosphorylated serine residues in the RNA polymerase II CTD |
| Major proteins | SPOC domain proteins, Spt6, Scp1, Fcp1, Ess1, influenza PA |
| Associated processes | Transcription elongation, RNA processing, termination, viral replication |
| Disease relevance | Cancer, neurodegeneration, viral pathogenesis |
What Is GO:1990269?
GO:1990269 is defined as the binding to phosphorylated serine residues in the C-terminal domain of RNA polymerase II. It is a molecular function that enables proteins to physically interact with the phosphorylated CTD, thereby mediating downstream events in transcription and RNA processing.
Why Is RNA polymerase II C-terminal domain phosphoserine binding Important in Cell Biology?
Understanding GO:1990269 is essential because it governs the recruitment of critical factors that determine the fate of nascent RNA transcripts. This binding function ensures proper transcription termination and RNA maturation, and its disruption can lead to widespread gene expression defects [1, 4]. Moreover, pathogens such as influenza virus hijack this interaction to control host transcription, making it a potential therapeutic target.
• Coordinates transcription with RNA processing and termination.
• Recruits phosphatases like Fcp1 and Scp1 to reset the CTD phosphorylation state [3, 5].
• Mediates the interaction between Pol II and splicing factors.
• Essential for embryonic development and cell viability.
• Targeted by viral proteins to shut off host transcription.
• Implicated in cancer through dysregulation of transcription termination.
• Provides a mechanism for signal transduction from the CTD to the RNA processing machinery.
• Enables the study of phosphorylation-dependent protein-protein interactions [2, 6].
What Happens During RNA polymerase II C-terminal domain phosphoserine binding?
Recognition of Phosphorylated CTD
In simple terms: Proteins with special domains recognize and attach to the phosphorylated tail of RNA polymerase II.
The CTD of RNA polymerase II contains multiple repeats of the sequence YSPTSPS. Phosphorylation of serine 2 and serine 5 within these repeats creates binding sites for specific protein modules. The SPOC domain, for example, has been shown to bind phosphorylated serine residues in the CTD with high specificity. Similarly, tandem SH2 domains from Spt6 bind to the phosphorylated CTD, facilitating its role in transcription elongation.
Recruitment of Co- and Post-transcriptional Regulators
In simple terms: Once bound, these proteins bring in other factors that process the RNA and end transcription.
Binding of proteins such as Spt6 and the SPOC domain-containing protein to the phosphorylated CTD serves as a platform for the recruitment of co-transcriptional regulators. This includes factors involved in RNA splicing, polyadenylation, and export. The cooperative interaction of termination factors with the CTD ensures efficient transcription termination.
Dephosphorylation and Recycling
In simple terms: Phosphatases are recruited to remove the phosphate marks, allowing the polymerase to start a new round of transcription.
After transcription termination, the CTD must be dephosphorylated to recycle Pol II. Phosphatases such as Fcp1 and Scp1 directly recognize the CTD and remove phosphates. Scp1 dephosphorylates serine 5, while Fcp1 acts on serine 2 [3, 5]. The binding of these phosphatases to the CTD is a key step in the transcription cycle.
Viral Hijacking of CTD Binding
In simple terms: Some viruses produce proteins that mimic cellular CTD-binding factors to take control of the host transcription machinery.
The influenza polymerase subunit PA contains a domain that binds to the phosphorylated CTD of Pol II. This interaction is essential for viral replication and allows the virus to steal capped RNA primers from host transcripts. This highlights the importance of CTD phosphoserine binding in host-pathogen interactions.
Key Genes Involved in GO:1990269 RNA polymerase II C-terminal domain phosphoserine binding
The following genes encode proteins that directly bind to the phosphorylated CTD of RNA polymerase II or regulate this interaction.
| Gene | Major Role | Research Relevance |
|---|---|---|
| SUPT6H | Tandem SH2 domains bind phosphorylated CTD; regulates elongation | Transcription elongation, chromatin remodeling |
| RPRD1A | SPOC domain binds phosphorylated CTD; couples transcription to RNA processing | Transcription termination, RNA processing |
| RPRD1B | SPOC domain binds phosphorylated CTD; regulates cell cycle | Cancer, transcription |
| CTDSP1 | Phosphatase that dephosphorylates CTD serine 5 | Transcription regulation, neuronal differentiation |
| CTDSP2 | Phosphatase that dephosphorylates CTD serine 5 | Cancer, transcription |
| CTDP1 | Phosphatase that dephosphorylates CTD serine 2 | Transcription termination, RNA processing |
| PIN1 | Peptidyl-prolyl isomerase with WW domain that binds phosphorylated CTD | Cell cycle, cancer, neurodegeneration |
| POLR2A | Largest subunit of RNA polymerase II; contains the CTD | Transcription, gene expression |
| PA (influenza) | Viral protein that binds phosphorylated CTD | Viral replication, host-pathogen interaction |
| SPT6 | Binds phosphorylated CTD; histone chaperone | Transcription elongation, chromatin |
| RTR1 | Phosphatase that regulates CTD phosphorylation | Transcription termination |
| ESS1 | Yeast homolog of PIN1; binds phosphorylated CTD | Transcription, cell cycle |
| SCP1 | Phosphatase that dephosphorylates CTD serine 5 | Transcription, neuronal development |
| FCP1 | Phosphatase that dephosphorylates CTD serine 2 | Transcription termination |
| RPRD2 | SPOC domain protein; binds phosphorylated CTD | RNA processing |
| SUPT5H | Binds phosphorylated CTD; regulates elongation | Transcription elongation |
| CDC73 | Binds phosphorylated CTD; part of Paf1 complex | Transcription elongation, cancer |
How Is RNA polymerase II C-terminal domain phosphoserine binding Regulated?
The binding of proteins to the phosphorylated CTD is regulated by the dynamic phosphorylation state of the CTD itself. Kinases such as CDK7 and CDK9 add phosphate groups to serine 2 and serine 5, while phosphatases like Fcp1 and Scp1 remove them [3, 5]. This cycle is tightly coupled to the transcription cycle. Additionally, the prolyl isomerase Ess1/Pin1 can regulate the conformation of the CTD, affecting binding. Viral proteins such as influenza PA can also modulate this interaction by competing with cellular factors.
RNA polymerase II C-terminal domain phosphoserine binding and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| RPRD1B | Cancer (tumor progression) | Knockout in cancer cell lines; xenograft models |
| PIN1 | Alzheimer's disease | Knockout mice; neuronal cell models |
| CTDSP1 | Cancer, neuronal differentiation | Point mutation of phosphatase domain; overexpression |
| PA (influenza) | Influenza virus replication | Knock-in of PA mutations in viral genome; cell culture |
| SUPT6H | Developmental disorders | Knockout zebrafish; CRISPR knock-in of patient mutations |
Cancer
Dysregulation of CTD phosphorylation and phosphoserine binding is observed in various cancers. For example, overexpression of the SPOC domain protein RPRD1B is associated with tumor progression. The phosphatase Scp1 is downregulated in some cancers, leading to altered CTD phosphorylation and gene expression.
Neurodegeneration
Pin1, a WW domain-containing isomerase that binds phosphorylated CTD, is implicated in Alzheimer's disease and other tauopathies. Its dysfunction leads to abnormal protein aggregation and neuronal death.
Viral Infections
Influenza virus depends on the interaction between its PA subunit and the phosphorylated CTD of Pol II for replication. This interaction is a potential target for antiviral drugs.
From RNA polymerase II C-terminal domain phosphoserine binding-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of SPOC domain binding affect transcription termination? | Knockout of RPRD1A/RPRD1B in HEK293 cells |
| How does a point mutation in the SH2 domain of Spt6 affect CTD binding? | Point mutation knock-in in HCT116 cells |
| Can a tagged version of Fcp1 rescue phosphatase function? | Knock-in of FLAG-tagged Fcp1 in HeLa cells |
| What is the effect of Pin1 overexpression on CTD phosphorylation? | Overexpression of PIN1 in neuronal cells |
| Which genes are regulated by Scp1-mediated dephosphorylation? | Knockout of CTDSP1 in mouse embryonic stem cells |
| Does influenza PA binding to CTD require serine 5 phosphorylation? | Point mutation of PA binding domain; viral infection assays |
How to Study the RNA polymerase II C-terminal domain phosphoserine binding Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Phospho-CTD pull-down | Direct binding to phosphorylated CTD | Identifying and characterizing CTD-binding proteins |
| ChIP-seq | Genomic localization of CTD-binding proteins | Mapping transcription elongation and termination sites |
| CRISPR knockout screen | Genes required for CTD binding function | Discovery of novel regulators |
| X-ray crystallography | 3D structure of binding domains | Understanding molecular recognition |
| NMR spectroscopy | Binding dynamics and affinity | Studying weak or transient interactions |
| Western blot with phospho-specific antibodies | CTD phosphorylation state | Monitoring kinase/phosphatase activity |
| RNA-seq | Transcriptional changes upon perturbation | Assessing impact on gene expression |
Phospho-CTD Pull-down Assays
Recombinant proteins or cell lysates can be incubated with phosphorylated CTD peptides to assess binding. This method is useful for identifying direct interactions and comparing binding affinities of mutant proteins [1, 2].
Chromatin Immunoprecipitation (ChIP)
ChIP with antibodies against phosphorylated CTD or CTD-binding proteins can map their genomic localization. This reveals the dynamics of binding across genes [4, 8].
CRISPR Screening
Genome-wide CRISPR knockout screens can identify genes required for CTD phosphoserine binding or its downstream effects. This approach is powerful for discovering novel regulators.
Structural Biology
X-ray crystallography and NMR can solve the structures of CTD-binding domains in complex with phosphorylated peptides. This provides atomic-level insights into specificity [2, 7].
How CRISPR Can Be Used to Study GO:1990269 RNA polymerase II C-terminal domain phosphoserine binding
Knockout
CRISPR knockout of genes encoding CTD-binding proteins (e.g., RPRD1A, SUPT6H) can reveal their essential roles in transcription and cell viability. Knockout cell lines are valuable for studying loss-of-function phenotypes [1, 2].
Point Mutation
Introducing point mutations in the phosphoserine-binding domains (e.g., in the SPOC domain of RPRD1B) allows precise dissection of binding specificity without affecting protein levels. This is crucial for separating binding from other functions.
Knock-in
Knock-in of tagged versions (e.g., FLAG, GFP) of CTD-binding proteins enables affinity purification and imaging. This helps track protein localization and interactions in live cells.
Overexpression
Overexpression of wild-type or mutant CTD-binding proteins can test for gain-of-function effects and dominant-negative phenotypes. This is useful for studying viral proteins like influenza PA.
How EDITGENE Supports RNA polymerase II C-terminal domain phosphoserine binding Research
Researchers studying RNA polymerase II C-terminal domain phosphoserine binding-related genes often need to determine whether a candidate gene is causally involved in transcription regulation, RNA processing, or disease. EDITGENE provides a comprehensive suite of CRISPR services to create precisely engineered cell models, enabling rigorous functional studies.
Contact EDITGENE today to design your custom CRISPR model for RNA polymerase II C-terminal domain phosphoserine binding research.
Frequently Asked Questions About RNA polymerase II C-terminal domain phosphoserine binding
What is RNA polymerase II C-terminal domain phosphoserine binding?
It is a molecular function (GO:1990269) where proteins bind to phosphorylated serine residues in the C-terminal domain of RNA polymerase II, facilitating transcription and RNA processing.
What genes are involved in RNA polymerase II C-terminal domain phosphoserine binding?
Key genes include SUPT6H, RPRD1A, RPRD1B, CTDSP1, CTDSP2, CTDP1, PIN1, and POLR2A, among others [1, 2, 3, 5, 6].
How does phosphorylation of the CTD regulate transcription?
Phosphorylation of serine 2 and serine 5 in the CTD creates binding sites for different factors that control elongation, termination, and RNA processing [1, 4].
What diseases are associated with defects in CTD phosphoserine binding?
Dysregulation is linked to cancer, neurodegeneration (e.g., Alzheimer's disease), and viral infections like influenza [1, 3, 6, 7].
Which proteins contain phosphoserine-binding domains for the CTD?
Proteins with SPOC domains, SH2 domains (e.g., Spt6), WW domains (e.g., Pin1/Ess1), and phosphatases like Fcp1 and Scp1 [1, 2, 5, 6].
How can I study CTD phosphoserine binding in the lab?
Common methods include phospho-CTD pull-down assays, ChIP-seq, CRISPR knockout screens, and structural biology techniques [1, 2, 4, 7].
What is the role of Spt6 in CTD phosphoserine binding?
Spt6 uses tandem SH2 domains to bind the phosphorylated CTD, coupling transcription elongation with chromatin remodeling.
How does influenza virus exploit CTD phosphoserine binding?
The influenza PA subunit binds to the phosphorylated CTD to steal capped RNA primers from host transcripts, a process essential for viral replication.
Can CRISPR be used to model CTD phosphoserine binding defects?
Yes, CRISPR knockout, point mutation, and knock-in models can precisely dissect the function of CTD-binding proteins [1, 2].
What is the SPOC domain and how does it relate to GO:1990269?
The SPOC domain is a phosphoserine-binding module that recognizes the phosphorylated CTD and bridges transcription with RNA processing.
Conclusion
GO:1990269, RNA polymerase II C-terminal domain phosphoserine binding, is a fundamental molecular function that orchestrates the recruitment of diverse factors to the transcription machinery. Its precise regulation is critical for gene expression, and its dysregulation contributes to cancer, neurodegeneration, and viral pathogenesis. Continued research using advanced CRISPR models and biochemical assays will further illuminate its mechanistic details and therapeutic potential.
References
- 1. Appel LM et al.. 2023. The SPOC domain is a phosphoserine binding module that bridges transcription machinery with co- and post-transcriptional regulators.. Nat Commun 14(1):166 PMID: 36631525
- 2. Liu J et al.. 2011. Solution structure of tandem SH2 domains from Spt6 protein and their binding to the phosphorylated RNA polymerase II C-terminal domain.. J Biol Chem 286(33):29218-29226 PMID: 21676864
- 3. Zhang Y et al.. 2006. Determinants for dephosphorylation of the RNA polymerase II C-terminal domain by Scp1.. Mol Cell 24(5):759-770 PMID: 17157258
- 4. Lunde BM et al.. 2010. Cooperative interaction of transcription termination factors with the RNA polymerase II C-terminal domain.. Nat Struct Mol Biol 17(10):1195-201 PMID: 20818393
- 5. Suh MH et al.. 2005. Fcp1 directly recognizes the C-terminal domain (CTD) and interacts with a site on RNA polymerase II distinct from the CTD.. Proc Natl Acad Sci U S A 102(48):17314-9 PMID: 16301539
- 6. Myers JK et al.. 2001. Phosphorylation of RNA polymerase II CTD fragments results in tight binding to the WW domain from the yeast prolyl isomerase Ess1.. Biochemistry 40(29):8479-86 PMID: 11456485
- 7. Lukarska M et al.. 2017. Structural basis of an essential interaction between influenza polymerase and Pol II CTD.. Nature 541(7635):117-121 PMID: 28002402
- 8. Han J et al.. 2016. A phosphorylation pattern-recognizing antibody specifically reacts to RNA polymerase II bound to exons.. Exp Mol Med 48(11):e271 PMID: 27857068
